The ability to generate senescent progeny as a mechanism underlying breast cancer cell heterogeneity

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Mumcuoglu, Mine ^a   Bagislar, Sevgi ^a,b   Yuzugullu, Haluk ^a,b   Alotaibi, Hani ^a   Senturk, Serif ^a   Telkoparan, Pelin ^a   Gur Dedeoglu, Bala ^a   Cingoz, Burcu ^a   Bozkurt, Betul ^c   Tazebay, Uygar H ^a   Yulug, Isik G ^a   Akcali, K Can ^a   Ozturk, Mehmet ^a,b  

^a BILKENT UNIVERSITY   (Turkey)

^b UNIV GRENOBLE ALPES   (France)

^c ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; ESTROGEN RECEPTOR; HERMES ANTIGEN; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL IMMORTALIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMORTAL STEM CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROGENY; SENESCENCE; SENESCENT STEM CELL; STEM CELL; BREAST TUMOR; CLUSTER ANALYSIS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

MUS;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, ESTROGEN;

EID: 77955287585     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011288     Document Type: Article

References (34)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
2. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
3. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800.
4. Stingl J, Caldas C (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7: 791-799.
5. Vargo-Gogola T, Rosen JM (2007) Modelling breast cancer: one size does not fit all. Nat Rev Cancer 7: 659-672.
6. Romanov SR, Kozakiewicz BK, Holst CR, Stampfer MR, Haupt LM, et al. (2001) Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409: 633-637.
7. Stampfer MR, Yaswen P (2003) Human epithelial cell immortalization as a step in carcinogenesis. Cancer Lett 194: 199-208.
8. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
9. Gur-Dedeoglu B, Konu O, Kir S, Ozturk AR, Bozkurt B, et al. (2008) A resampling-based meta-analysis for detection of differential gene expression in breast cancer. BMC Cancer 8: 396.
10. Ozturk N, Erdal E, Mumcuoglu M, Akcali KC, Yalcin O, et al. (2006) Reprogramming of replicative senescence in hepatocellular carcinoma-derived cells. Proc Natl Acad Sci U S A 103: 2178-2183.
11. Dimri GP, Lee X, Basile G, Acosta M, Scott G, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92: 9363-9367.
12. Alotaibi H, Yaman EC, Demirpence E, Tazebay UH (2006) Unliganded estrogen receptor-alpha activates transcription of the mammary gland Na+/I- symporter gene. Biochem Biophys Res Commun 345: 1487-1496.
13. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, et al. (2006) Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25: 2273-2284.
14. Stingl J (2009) Detection and analysis of mammary gland stem cells. J Pathol 217: 229-241.
15. Campisi J, d'Adda di Fagagna F (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8: 729-740.
16. Wei W, Sedivy JM (1999) Differentiation between senescence (M1) and crisis (M2) in human fibroblast cultures. Exp Cell Res 253: 519-522.
17. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, et al. (1998) Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396: 84-88.
18. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, et al. (2003) Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 22: 4212-4222.
19. Garbe JC, Holst CR, Bassett E, Tlsty T, Stampfer MR (2007) Inactivation of p53 function in cultured human mammary epithelial cells turns the telomere-length dependent senescence barrier from agonescence into crisis. Cell Cycle 6: 1927-1936.
20. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, et al. (2000) Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A 97: 9042-9046.
21. Mukherjee S, Conrad SE (2005) c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 280: 17617-17625.
22. Dubik D, Shiu RP (1992) Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7: 1587-1594.
23. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS (1986) Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A 83: 2496-2500.
24. Booth BW, Smith GH (2006) Estrogen receptor-alpha and progesterone receptor are expressed in label-retaining mammary epithelial cells that divide asymmetrically and retain their template DNA strands. Breast Cancer Res 8: R49.
25. Shyamala G, Chou YC, Cardiff RD, Vargis E (2006) Effect of c-neu/ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology. Cancer Res 66: 10391-10398.
26. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
27. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, et al. (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273.
28. Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ (2006) CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res 8: R7.
29. Yeh IT, Mies C (2008) Application of immunohistochemistry to breast lesions. Arch Pathol Lab Med 132: 349-358.
30. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393-10398.
31. Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, et al. (2007) Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A 104: 13028-13033.
32. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, et al. (2008) The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10: R53.
33. Ford CE, Ekstrom EJ, Andersson T (2009) Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells. Proc Natl Acad Sci U S A 106: 3919-3924.
34. (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451-1467.